therapeuticЮжно-Российский журнал терапевтической практикиSouth Russian Journal of Therapeutic Practice2712-8156РостГМУ10.21886/2712-8156-2024-5-2-29-37therapeutic-502Research ArticleОБЗОРЫREVIEWSНАЖБП — предиктор высокого риска развития и ко-фактор прогрессирования сердечно-сосудистых заболеванийNAFLD is a predictor of high risk of development and a co-factor in the progression of cardiovascular diseaseshttps://orcid.org/0000-0003-4160-8154ШавкутаГ. В.ShavkutaG. V.

Шавкута Галина Владимировна - д.м.н., профессор, заведующая кафедрой общей врачебной практики (семейной медицины) (с курсам гериатрии и физиотерапии).

Ростов-на-Дону

Galina V. Shavkuta - Dr. Sci. (Med.), Prof., Head of the Department of General Medical Practice (Family Medicine) (with courses in geriatrics and physiotherapy).

Rostov-on-Don

semmed@mail.ruhttps://orcid.org/0000-0002-8844-2465ТуркинаC. В.TurkinaS. V.

Туркина Светлана Владимировна - д.м.н., профессор кафедры внутренних болезней.

Волгоград

Svetlana V. Turkina - Dr. Sci. (Med.), Prof. of the Department of Internal Medicine.

Volgograd

turkinasv@rambler.ruФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава РоссииРоссияRostov State Medical UniversityRussian FederationФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава РоссииРоссияVolgograd State Medical UniversityRussian Federation202424062024522937Copyright © Шавкута Г.В., Туркина C.В., 20242024Шавкута Г.В., Туркина C.В.Shavkuta G.V., Turkina S.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.therapeutic-j.ru/jour/article/view/502

На сегодняшний день неалкогольная жировая болезнь печени (НАЖБП) является наиболее распространённой хронической патологией печени и уже на стадии стеатоза обуславливает высокий риск развития сердечно-сосудистых заболеваний (ССЗ). Получены убедительные доказательства, что ССЗ являются наиболее частой причиной смерти у пациентов с НАЖБП. Единые факторы риска (инсулинорезистентность, абдоминальное ожирение, дислипидемия, гиперурикемия, хроническое заболевание почек и сахарный диабет 2 типа) и сходные патофизиологические механизмы (эндотелиальная дисфункция, гиперлипидемия, системное воспаление, образование/нестабильность бляшек, окислительный стресс) НАЖБП и ССЗ позволяют рассматривать НАЖБП не только как ключевой фактор риска развития ССЗ, но и как ко-фактор прогрессирования кардиальной патологии. Прогрессирование самой НАЖБП приводит к более тяжёлому течению ССЗ.

To date, nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver pathology and already at the stage of steatosis causes a high risk of developing cardiovascular diseases (CVD). Convincing evidence has been obtained that CVD is the most common cause of death in patients with NAFLD. Common risk factors (insulin resistance, abdominal obesity, dyslipidemia, hyperuricemia, chronic kidney disease and type 2 diabetes mellitus) and similar pathophysiological mechanisms (endothelial dysfunction, changes in lipid metabolism, systemic inflammation, plaque formation/instability, oxidative stress) of NAFLD and CVD, allow us to consider NAFLD not only as a key risk factor for the development of CVD, but also as a co-factor in the progression of cardiac pathology. The progression of NAFLD itself leads to a more severe course of CVD.

неалкогольная жировая болезнь печени (НАЖБП)сердечно-сосудистые заболевания (ССЗ)кардиометаболическая коморбидностьэндотелиальная дисфункциягиперлипидемиясистемное воспалениеобразование/нестабильность бляшекокислительный стрессинсулинорезистентностьnonalcoholic fatty liver disease (NAFLD)cardiovascular diseases (CVD)cardiometabolic comorbidityendothelial dysfunctionchanges in lipid metabolismsystemic inflammationplaque formation/instabilityoxidative stressinsulin resistanceнетReferencesWorld Health Organization. Global Health Estimates 2019: Disease Burden by Cause, Age, Sex, by Country and by Region, 2000–2019. WHO; Geneva, Switzerland: 2021.World Health Organization. Global Health Estimates 2019: Disease Burden by Cause, Age, Sex, by Country and by Region, 2000–2019. WHO; Geneva, Switzerland: 2021.Arnett D.K., Blumenthal R.S., Albert M.A., Buroker A.B., Goldberger Z.D., Hahn E.J. et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;74:1376–1414. DOI: 10.1016/j.jacc.2019.03.010Arnett D.K., Blumenthal R.S., Albert M.A., Buroker A.B., Goldberger Z.D., Hahn E.J. et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;74:1376–1414. DOI: 10.1016/j.jacc.2019.03.010Лазебник Л. Б., Туркина С. В. НАЖБП-ассоциированная коморбидность. Экспериментальная и клиническая гастроэнтерология. 2021;194(10):5–13. DOI: 10.31146/1682-8658-ecg-194-10-5-13Lazebnik L.B., Turkina S.V. NAFLD Associated Comorbidity. Experimental and Clinical Gastroenterology. 2021;(10):5-13. (In Russ.) DOI: 10.31146/1682-8658-ecg-194-10-5-13Ивашкин В.Т., Маевская М.В., Жаркова М.С., Котовская Ю.В., Ткачева О.Н., Трошина Е.А. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):104-140. DOI: 10.22416/1382-4376-2022-32-4-104-140Ivashkin V.T., Maevskaya M.V., Zharkova M.S., Kotovskaya Yu.V., Tkacheva O.N., Troshina E.A., et al. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):104-140. (In Russ.) DOI: 10.22416/1382-4376-2022-32-4-104-140Маевская М.В., Котовская Ю.В., Ивашкин В.Т., Ткачева О.Н., Трошина Е.А., Шестакова М.В. и др. Национальный Консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив. 2022;94(2):216–253. DOI: 10.26442/00403660.2022.02.201363Mayevskaya M.V., Kotovskaya Yu.V., Ivashkin V.T., Tkacheva O.N., Troshina E.A., Shestakova M.V. et al. National Consensus for physicians on the management of adult patients with non-alcoholic fatty liver disease and its main comorbid conditions. Terapevticheskij arhiv. 2022;94(2):216–253. (In Russ.) DOI: 10.26442/00403660.2022.02.201363Moolla A, Motohashi K, Marjot T, Shard A, Ainsworth M, Gray A. et al. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. Frontline Gastroenterol. 2019;10(4):337-346. DOI: 10.1136/flgastro-2018-101155Moolla A, Motohashi K, Marjot T, Shard A, Ainsworth M, Gray A. et al. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. Frontline Gastroenterol. 2019;10(4):337-346. DOI: 10.1136/flgastro-2018-101155Targher G., Tilg H., Byrne C.D. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578-588. DOI: 10.1016/S2468-1253(21)00020-0Targher G., Tilg H., Byrne C.D. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578-588. DOI: 10.1016/S2468-1253(21)00020-0Ma W., Wu W., Wen W., Xu F., Han D., Lyu J. et al. Association of NAFLD with cardiovascular disease and all-cause mortality: a large-scale prospective cohort study based on UK Biobank. Ther Adv Chronic Dis. 2022;13:20406223221122478. DOI: 10.1177/20406223221122478Ma W., Wu W., Wen W., Xu F., Han D., Lyu J. et al. Association of NAFLD with cardiovascular disease and all-cause mortality: a large-scale prospective cohort study based on UK Biobank. Ther Adv Chronic Dis. 2022;13:20406223221122478. DOI: 10.1177/20406223221122478Lonardo A., Mantovani A., Targher G., Baffy G. Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications. Int. J. Mol. 2022;23(21):13320. DOI: 10.3390/ijms232113320Lonardo A., Mantovani A., Targher G., Baffy G. Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications. Int. J. Mol. 2022;23(21):13320. DOI: 10.3390/ijms232113320Kosmalski M., Śliwińska A., Drzewoski J. Non-Alcoholic Fatty Liver Disease or Type 2 Diabetes Mellitus—The Chicken or the Egg Dilemma. Biomedicines. 2023;11(4):1097. DOI: 10.3390/biomedicines11041097Kosmalski M., Śliwińska A., Drzewoski J. Non-Alcoholic Fatty Liver Disease or Type 2 Diabetes Mellitus—The Chicken or the Egg Dilemma. Biomedicines. 2023;11(4):1097. DOI: 10.3390/biomedicines11041097Mantovani A., Petracca G., Beatrice G., Csermely A., Tilg H., Byrne C.D. et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut. 2022;71(4):778-788. DOI: 10.1136/gutjnl-2021-324191Mantovani A., Petracca G., Beatrice G., Csermely A., Tilg H., Byrne C.D. et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut. 2022;71(4):778-788. DOI: 10.1136/gutjnl-2021-324191McHenry S., Zong X., Shi M., Fritz C.D.L., Pedersen K.S., Peterson L.R. et al. Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancers. Hepatol Commun. 2022;6(12):3299-3310. DOI: 10.1002/hep4.2073McHenry S., Zong X., Shi M., Fritz C.D.L., Pedersen K.S., Peterson L.R. et al. Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancers. Hepatol Commun. 2022;6(12):3299-3310. DOI: 10.1002/hep4.2073Taylor R.S., Taylor R.J., Bayliss S., Hagström H., Nasr P., Schattenberg J.M. et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology. 2020;158(6):1611-1625.e12. DOI: 10.1053/j.gastro.2020.01.043Taylor R.S., Taylor R.J., Bayliss S., Hagström H., Nasr P., Schattenberg J.M. et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology. 2020;158(6):1611-1625.e12. DOI: 10.1053/j.gastro.2020.01.043Simon T.G., Roelstraete B., Khalili H., Hagström H., Ludvigsson J.F. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021;70(7):1375–1382. DOI: 10.1136/gutjnl-2020–322786.Simon T.G., Roelstraete B., Khalili H., Hagström H., Ludvigsson J.F. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021;70(7):1375–1382. DOI: 10.1136/gutjnl-2020–322786.Oni E.T., Agatston A.S., Blaha M.J., Fialkow J., Cury R., Sposito A. et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013;230(2):258-267. DOI: 10.1016/j.atherosclerosis.2013.07.052Oni E.T., Agatston A.S., Blaha M.J., Fialkow J., Cury R., Sposito A. et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013;230(2):258-267. DOI: 10.1016/j.atherosclerosis.2013.07.052Zeb I., Li D., Budoff M.J., Katz R., Lloyd-Jones D., Agatston A. Nonalcoholic Fatty Liver Disease and Incident Cardiac Events: The Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol. 2016;67(16):1965-1966. DOI: 10.1016/j.jacc.2016.01.070Zeb I., Li D., Budoff M.J., Katz R., Lloyd-Jones D., Agatston A. Nonalcoholic Fatty Liver Disease and Incident Cardiac Events: The Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol. 2016;67(16):1965-1966. DOI: 10.1016/j.jacc.2016.01.070Mantovani A., Mingolla L., Rigolon R., Pichiri I., Cavalieri V., Zoppini G. et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes. Int J Cardiol. 2016;225:387-391. DOI: 10.1016/j.ijcard.2016.10.040Mantovani A., Mingolla L., Rigolon R., Pichiri I., Cavalieri V., Zoppini G. et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes. Int J Cardiol. 2016;225:387-391. DOI: 10.1016/j.ijcard.2016.10.040Targher G., Byrne C.D., Lonardo A., Zoppini G., Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589-600. DOI: 10.1016/j.jhep.2016.05.013Targher G., Byrne C.D., Lonardo A., Zoppini G., Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589-600. DOI: 10.1016/j.jhep.2016.05.013Adams L.A., Anstee Q.M., Tilg H., Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138-1153. DOI: 10.1136/gutjnl-2017-313884Adams L.A., Anstee Q.M., Tilg H., Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138-1153. DOI: 10.1136/gutjnl-2017-313884Mellinger J.L., Pencina K.M., Massaro J.M., Hoffmann U., Seshadri S., Fox C.S. et al. Hepatic steatosis and cardiovascular disease outcomes: An analysis of the Framingham Heart Study. J Hepatol. 2015;63(2):470-476. DOI: 10.1016/j.jhep.2015.02.045Mellinger J.L., Pencina K.M., Massaro J.M., Hoffmann U., Seshadri S., Fox C.S. et al. Hepatic steatosis and cardiovascular disease outcomes: An analysis of the Framingham Heart Study. J Hepatol. 2015;63(2):470-476. DOI: 10.1016/j.jhep.2015.02.045Haddad T.M., Hamdeh S., Kanmanthareddy A., Alla V.M. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis. Diabetes Metab Syndr. 2017;11 Suppl 1:S209-S216. DOI: 10.1016/j.dsx.2016.12.033Haddad T.M., Hamdeh S., Kanmanthareddy A., Alla V.M. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis. Diabetes Metab Syndr. 2017;11 Suppl 1:S209-S216. DOI: 10.1016/j.dsx.2016.12.033Osawa K., Miyoshi T., Yamauchi K., Koyama Y., Nakamura K., Sato S. et al. Nonalcoholic Hepatic Steatosis Is a Strong Predictor of High-Risk Coronary-Artery Plaques as Determined by Multidetector CT. PLoS One. 2015;10(6):e0131138. DOI: 10.1371/journal.pone.0131138Osawa K., Miyoshi T., Yamauchi K., Koyama Y., Nakamura K., Sato S. et al. Nonalcoholic Hepatic Steatosis Is a Strong Predictor of High-Risk Coronary-Artery Plaques as Determined by Multidetector CT. PLoS One. 2015;10(6):e0131138. DOI: 10.1371/journal.pone.0131138Keskin M., Hayıroğlu M.İ., Uzun A.O., Güvenç T.S., Şahin S., Kozan Ö. Effect of Nonalcoholic Fatty Liver Disease on In-Hospital and Long-Term Outcomes in Patients With ST-Segment Elevation Myocardial Infarction. Am J Cardiol. 2017;120(10):1720-1726. DOI: 10.1016/j.amjcard.2017.07.107Keskin M., Hayıroğlu M.İ., Uzun A.O., Güvenç T.S., Şahin S., Kozan Ö. Effect of Nonalcoholic Fatty Liver Disease on In-Hospital and Long-Term Outcomes in Patients With ST-Segment Elevation Myocardial Infarction. Am J Cardiol. 2017;120(10):1720-1726. DOI: 10.1016/j.amjcard.2017.07.107Евстифеева С.Е., Шальнова С.А., Куценко В.А., Яровая Е.Б., Баланова Ю.А., Имаева А.Э. и др. Распространенность неалкогольной жировой болезни печени среди населения трудоспособного возраста: ассоциации с социально-демографическими показателями и поведенческими факторами риска (данные ЭССЕ-РФ-2). Кардиоваскулярная терапия и профилактика. 2022;21(9):3356. DOI: 10.15829/1728-8800-2022-3356Evstifeeva S.E., Shalnova S.A., Kutsenko V.A., Yarovaya E.B., Balanova Yu.A., Imaeva A.E. et al. Prevalence of non-alcoholic fatty liver disease among the working-age population: associations with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data). Cardiovascular Therapy and Prevention. 2022;21(9):3356. (In Russ.). DOI: 10.15829/1728-8800-2022-3356Chiriac S., Stanciu C., Girleanu I., Cojocariu C., Sfarti C., Singeap A-M. et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter. Can J Gastroenterol Hepatol. 2021;2021:6696857. DOI: 10.1155/2021/6696857Chiriac S., Stanciu C., Girleanu I., Cojocariu C., Sfarti C., Singeap A-M. et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter. Can J Gastroenterol Hepatol. 2021;2021:6696857. DOI: 10.1155/2021/6696857Francque S. The Liver and the Cardiovascular System: Two of a Kind? J Am Heart Assoc. 2021;10(8):e020286. DOI: 10.1161/JAHA.121.020286Francque S. The Liver and the Cardiovascular System: Two of a Kind? J Am Heart Assoc. 2021;10(8):e020286. DOI: 10.1161/JAHA.121.020286Stahl E.P., Dhindsa D.S., Lee S.K., Sandesara P.B., Chalasani N.P., Sperling L.S. Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(8):948-963. DOI: 10.1016/j.jacc.2018.11.050Stahl E.P., Dhindsa D.S., Lee S.K., Sandesara P.B., Chalasani N.P., Sperling L.S. Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(8):948-963. DOI: 10.1016/j.jacc.2018.11.050Kasper P., Martin A., Lang S., Kütting F., Goeser T., Demir M. et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110(7):921-937. DOI: 10.1007/s00392-020-01709-7Kasper P., Martin A., Lang S., Kütting F., Goeser T., Demir M. et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110(7):921-937. DOI: 10.1007/s00392-020-01709-7Lechner K., McKenzie A.L., Kränkel N., Von Schacky C., Worm N., Nixdorff U. et al. High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation. Metab Syndr Relat Disord. 2020;18(4):176-185. DOI: 10.1089/met.2019.0115Lechner K., McKenzie A.L., Kränkel N., Von Schacky C., Worm N., Nixdorff U. et al. High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation. Metab Syndr Relat Disord. 2020;18(4):176-185. DOI: 10.1089/met.2019.0115Libby P., Everett B.M. Novel Antiatherosclerotic Therapies. Arterioscler Thromb Vasc Biol. 2019;39(4):538-545. DOI: 10.1161/ATVBAHA.118.310958Libby P., Everett B.M. Novel Antiatherosclerotic Therapies. Arterioscler Thromb Vasc Biol. 2019;39(4):538-545. DOI: 10.1161/ATVBAHA.118.310958Francque S.M., van der Graaff D., Kwanten W.J. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol. 2016;65(2):425-43. DOI: 10.1016/j.jhep.2016.04.005Francque S.M., van der Graaff D., Kwanten W.J. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol. 2016;65(2):425-43. DOI: 10.1016/j.jhep.2016.04.005Young S., Tariq R., Provenza J., Satapathy S.K., Faisal K., Choudhry A., et al. Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta-Analysis. Hepatol Commun. 2020;4(7):953-972. DOI: 10.1002/hep4.1519Young S., Tariq R., Provenza J., Satapathy S.K., Faisal K., Choudhry A., et al. Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta-Analysis. Hepatol Commun. 2020;4(7):953-972. DOI: 10.1002/hep4.1519Zakerkish M, Hoseinian A, Alipour M, Payami SP. The Association between Cardio-metabolic and hepatic indices and anthropometric measures with metabolically obesity phenotypes: a cross-sectional study from the Hoveyzeh Cohort Study. BMC Endocr Disord. 2023;23(1):122. DOI: 10.1186/s12902-023-01372-9Zakerkish M, Hoseinian A, Alipour M, Payami SP. The Association between Cardio-metabolic and hepatic indices and anthropometric measures with metabolically obesity phenotypes: a cross-sectional study from the Hoveyzeh Cohort Study. BMC Endocr Disord. 2023;23(1):122. DOI: 10.1186/s12902-023-01372-9Packer M. Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. J Am Coll Cardiol. 2018;71(20):2360-2372. DOI: 10.1016/j.jacc.2018.03.509Packer M. Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. J Am Coll Cardiol. 2018;71(20):2360-2372. DOI: 10.1016/j.jacc.2018.03.509Gruzdeva O., Uchasova E., Dyleva Y., Borodkina D., Akbasheva O., Antonova L. et al. Adipocytes Directly Affect Coronary Artery Disease Pathogenesis via Induction of Adipokine and Cytokine Imbalances. Front Immunol. 2019;10:2163. DOI: 10.3389/fimmu.2019.02163Gruzdeva O., Uchasova E., Dyleva Y., Borodkina D., Akbasheva O., Antonova L. et al. Adipocytes Directly Affect Coronary Artery Disease Pathogenesis via Induction of Adipokine and Cytokine Imbalances. Front Immunol. 2019;10:2163. DOI: 10.3389/fimmu.2019.02163Meex R.C.R., Watt M.J. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017;13(9):509–520. DOI: 10.1038/nrendo.2017.56Meex R.C.R., Watt M.J. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017;13(9):509–520. DOI: 10.1038/nrendo.2017.56Jensen-Cody S.O., Potthoff M.J. Hepatokines and metabolism: Deciphering communication from the liver. Mol Metab. 2021;44:101138. DOI: 10.1016/j.molmet.2020.101138Jensen-Cody S.O., Potthoff M.J. Hepatokines and metabolism: Deciphering communication from the liver. Mol Metab. 2021;44:101138. DOI: 10.1016/j.molmet.2020.101138Lee S., Norheim F., Gulseth H.L. Langleite T.M., Kolnes K.J., Tangen D.S. et al. Interaction between plasma fetuin‐A and free fatty acids predicts changes in insulin sensitivity in response to long‐term exercise. Physiol Rep. 2017;5(5):e13183. DOI: 10.14814/phy2.13183Lee S., Norheim F., Gulseth H.L. Langleite T.M., Kolnes K.J., Tangen D.S. et al. Interaction between plasma fetuin‐A and free fatty acids predicts changes in insulin sensitivity in response to long‐term exercise. Physiol Rep. 2017;5(5):e13183. DOI: 10.14814/phy2.13183Niederseer D., Wernly B., Aigner E., Stickel F., Datz C. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J Clin Med. 2021;10(3):467. DOI: 10.3390/jcm10030467Niederseer D., Wernly B., Aigner E., Stickel F., Datz C. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J Clin Med. 2021;10(3):467. DOI: 10.3390/jcm10030467Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121(4 Pt 1):1244-1263. DOI: 10.1016/0002-8703(91)90694-dDzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121(4 Pt 1):1244-1263. DOI: 10.1016/0002-8703(91)90694-dTargher G., Lonardo A., Byrne C.D. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 2018;14(2):99-114. DOI: 10.1038/nrendo.2017.173Targher G., Lonardo A., Byrne C.D. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 2018;14(2):99-114. DOI: 10.1038/nrendo.2017.173Targher G., Mantovani A., Pichiri I., Mingolla L., Cavalieri V., Mantovani W. et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care. 2014;37(6):1729-36. DOI: 10.2337/dc13-2704Targher G., Mantovani A., Pichiri I., Mingolla L., Cavalieri V., Mantovani W. et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care. 2014;37(6):1729-36. DOI: 10.2337/dc13-2704Targher G., Bertolini L., Rodella S., Zoppini G., Lippi G., Day C. et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008;51(3):444-50. DOI: 10.1007/s00125-007-0897-4Targher G., Bertolini L., Rodella S., Zoppini G., Lippi G., Day C. et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008;51(3):444-50. DOI: 10.1007/s00125-007-0897-4Li Y., Zhu S., Li B., Shao X., Liu X., Liu A. et al. Association between non-alcoholic fatty liver disease and chronic kidney disease in population with prediabetes or diabetes. Int Urol Nephrol. 2014;46(9):1785-1791. DOI: 10.1007/s11255-014-0796-9Li Y., Zhu S., Li B., Shao X., Liu X., Liu A. et al. Association between non-alcoholic fatty liver disease and chronic kidney disease in population with prediabetes or diabetes. Int Urol Nephrol. 2014;46(9):1785-1791. DOI: 10.1007/s11255-014-0796-9Nampoothiri R.V., Duseja A., Rathi M., Agrawal S., Sachdeva N., Mehta M. et al. Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is Related to the Presence of Diabetes Mellitus and Severity of Liver Disease. J Clin Exp Hepatol. 2019;9(1):22-28. DOI: 10.1016/j.jceh.2017.12.005.Nampoothiri R.V., Duseja A., Rathi M., Agrawal S., Sachdeva N., Mehta M. et al. Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is Related to the Presence of Diabetes Mellitus and Severity of Liver Disease. J Clin Exp Hepatol. 2019;9(1):22-28. DOI: 10.1016/j.jceh.2017.12.005.Saito H., Tanabe H., Kudo A. Machii N., Higa M., Yamaguchi S. et al. High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes. Sci Rep. 2021;11(1):11753. DOI: 10.1038/s41598-021-88285-6.Saito H., Tanabe H., Kudo A. Machii N., Higa M., Yamaguchi S. et al. High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes. Sci Rep. 2021;11(1):11753. DOI: 10.1038/s41598-021-88285-6.Alper A.T., Hasdemir H., Sahin S., Ontürk E., Akyol A., Nurkalem Z. et al. The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome. Turk Kardiyol Dern Ars. 2008;36(6):376-381. PMID: 19155640Alper A.T., Hasdemir H., Sahin S., Ontürk E., Akyol A., Nurkalem Z. et al. The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome. Turk Kardiyol Dern Ars. 2008;36(6):376-381. PMID: 19155640Boddi M., Tarquini R., Chiostri M., Marra F., Valente S., Giglioli C. et al. Nonalcoholic fatty liver in nondiabetic patients with acute coronary syndromes. Eur J Clin Invest. 2013;43(5):429-438. DOI: 10.1111/eci.12065Boddi M., Tarquini R., Chiostri M., Marra F., Valente S., Giglioli C. et al. Nonalcoholic fatty liver in nondiabetic patients with acute coronary syndromes. Eur J Clin Invest. 2013;43(5):429-438. DOI: 10.1111/eci.12065Wang X., Shen L., Shen Y., Han .F, Ji Z. Association between Non-alcoholic Fatty Liver Disease and the Severity of Coronary Artery Stenosis in Eastern Chinese Population. Hepat Mon. 2021;21(11):e122772. DOI: 10.5812/hepatmon.122772Wang X., Shen L., Shen Y., Han .F, Ji Z. Association between Non-alcoholic Fatty Liver Disease and the Severity of Coronary Artery Stenosis in Eastern Chinese Population. Hepat Mon. 2021;21(11):e122772. DOI: 10.5812/hepatmon.122772Perera N., Indrakumar J., Abeysinghe W.V., Fernando V., Samaraweera W.M., Lawrence J.S.. Non alcoholic fatty liver disease increases the mortality from acute coronary syndrome: an observational study from Sri Lanka. BMC Cardiovasc Disord. 2016;16:37. DOI: 10.1186/s12872-016-0212-8Perera N., Indrakumar J., Abeysinghe W.V., Fernando V., Samaraweera W.M., Lawrence J.S.. Non alcoholic fatty liver disease increases the mortality from acute coronary syndrome: an observational study from Sri Lanka. BMC Cardiovasc Disord. 2016;16:37. DOI: 10.1186/s12872-016-0212-8Emre A., Terzi S., Celiker E., Sahin S., Yazıcı S., Erdem A. Impact of Nonalcoholic Fatty Liver Disease on Myocardial Perfusion in Nondiabetic Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Am J Cardiol. 2015;116(12):1810-1814. DOI: 10.1016/j.amjcard.2015.09.021Emre A., Terzi S., Celiker E., Sahin S., Yazıcı S., Erdem A. Impact of Nonalcoholic Fatty Liver Disease on Myocardial Perfusion in Nondiabetic Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Am J Cardiol. 2015;116(12):1810-1814. DOI: 10.1016/j.amjcard.2015.09.021Wong V.W., Wong G.L., Yeung J.C., Fung C.Y., Chan J.K., Chang Z.H. et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatology. 2016;63(3):754-763. DOI: 10.1002/hep.28253Wong V.W., Wong G.L., Yeung J.C., Fung C.Y., Chan J.K., Chang Z.H. et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatology. 2016;63(3):754-763. DOI: 10.1002/hep.28253Borges-Canha M., Neves J.S., Libânio D., Von-Hafe M., Vale C., Araújo-Martins M. et al. Association between nonalcoholic fatty liver disease and cardiac function and structure-a meta-analysis. Endocrine. 2019;66(3):467-476. DOI: 10.1007/s12020-019-02070-0Borges-Canha M., Neves J.S., Libânio D., Von-Hafe M., Vale C., Araújo-Martins M. et al. Association between nonalcoholic fatty liver disease and cardiac function and structure-a meta-analysis. Endocrine. 2019;66(3):467-476. DOI: 10.1007/s12020-019-02070-0Wijarnpreecha K., Lou S., Panjawatanan P., Cheungpasitporn W., Pungpapong S., Lukens F.J. et al. Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Dig Liver Dis. 2018;50(11):1166-1175. DOI: 10.1016/j.dld.2018.09.004Wijarnpreecha K., Lou S., Panjawatanan P., Cheungpasitporn W., Pungpapong S., Lukens F.J. et al. Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Dig Liver Dis. 2018;50(11):1166-1175. DOI: 10.1016/j.dld.2018.09.004Мantovani A., Petracca G., Csermely A., Beatrice G., Bonapace S., Rossi A. et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut. 2022:gutjnl-2022-327672. DOI: 10.1136/gutjnl-2022-327672Мantovani A., Petracca G., Csermely A., Beatrice G., Bonapace S., Rossi A. et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut. 2022:gutjnl-2022-327672. DOI: 10.1136/gutjnl-2022-327672Yoshihisa A., Sato Y., Yokokawa T., Sato T., Suzuki S., Oikawa M., et al. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction. ESC Heart Fail. 2018;5(2):262-270. DOI: 10.1002/ehf2.12222Yoshihisa A., Sato Y., Yokokawa T., Sato T., Suzuki S., Oikawa M., et al. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction. ESC Heart Fail. 2018;5(2):262-270. DOI: 10.1002/ehf2.12222Trovato F.M., Martines G.F., Catalano D., Musumeci G., Pirri C., Trovato G.M. Echocardiography and NAFLD (non-alcoholic fatty liver disease). Int J Cardiol. 2016;221:275-279. DOI: 10.1016/j.ijcard.2016.06.180Trovato F.M., Martines G.F., Catalano D., Musumeci G., Pirri C., Trovato G.M. Echocardiography and NAFLD (non-alcoholic fatty liver disease). Int J Cardiol. 2016;221:275-279. DOI: 10.1016/j.ijcard.2016.06.180Zhang Z., Wang P., Guo F., Liu X., Luo T., Guan Y., et al. Chronic heart failure in patients with nonalcoholic fatty liver disease: prevalence, clinical features, and relevance. J Int Med Res. 2018;46(9):3959-3969. DOI: 10.1177/0300060518782780Zhang Z., Wang P., Guo F., Liu X., Luo T., Guan Y., et al. Chronic heart failure in patients with nonalcoholic fatty liver disease: prevalence, clinical features, and relevance. J Int Med Res. 2018;46(9):3959-3969. DOI: 10.1177/0300060518782780Valbusa F., Agnoletti D., Scala L., Grillo C., Arduini P., Bonapace S. et al. Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure. Int J Cardiol. 2018;265:162-168. DOI: 10.1016/j.ijcard.2018.04.129Valbusa F., Agnoletti D., Scala L., Grillo C., Arduini P., Bonapace S. et al. Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure. Int J Cardiol. 2018;265:162-168. DOI: 10.1016/j.ijcard.2018.04.129Лазебник Л.Б., Голованова Е.В., Туркина С.В., Райхельсон К.Л., Оковитый С.В., Драпкина О.М. и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;185(1):4-52. DOI: 10.31146/1682-8658-ecg-185-1-4-52Lazebnik L.B., Golovanova E.V., Turkina S.V., Raikhelson K.L., Okovityy S.V., Drapkina O.M., et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4-52. (In Russ.) DOI: 10.31146/1682-8658-ecg-185-1-4-52

The authors declare that there are no conflicts of interest present.